- Home
- GH vs WFRD Comparison
GH vs WFRD Comparison
Compare GH & WFRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GH | WFRD |
|---|---|---|
| Founded | 2011 | 1941 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.1B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | GH | WFRD |
|---|---|---|
| Price | $103.60 | $74.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 9 |
| Target Price | $79.19 | ★ $85.67 |
| AVG Volume (30 Days) | ★ 2.9M | 698.9K |
| Earning Date | 10-29-2025 | 10-21-2025 |
| Dividend Yield | N/A | ★ 1.34% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.52 |
| Revenue | $902,569,000.00 | ★ $4,970,000,000.00 |
| Revenue This Year | $34.72 | N/A |
| Revenue Next Year | $26.46 | N/A |
| P/E Ratio | ★ N/A | $13.55 |
| Revenue Growth | ★ 30.38 | N/A |
| 52 Week Low | $29.91 | $36.74 |
| 52 Week High | $112.43 | $86.64 |
Technical Indicators
Market Signals| Indicator | GH | WFRD |
|---|---|---|
| Relative Strength Index (RSI) | 66.40 | 57.36 |
| Support Level | $98.23 | $68.49 |
| Resistance Level | $112.43 | $77.64 |
| Average True Range (ATR) | 5.44 | 3.20 |
| MACD | -0.54 | 0.05 |
| Stochastic Oscillator | 64.46 | 68.74 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.